Adjutec Pharma’s vision is to develop and provide novel antibiotic resistance breakers in order to retain efficacy and facilitate reduced use of antibiotics. Its lead product is a metallo-β-lactamase resistance breaker, APC148. APC148 has demonstrated efficacy against a large panel of multidrug-resistant isolates, the synthesis route is simple and scalable, and preliminary in vitro tests indicate a favorable toxicity profile.
The management team consists of CEO Bjørn Klem, who has 30 years R&D experience at NAF-Lab, Hydro Pharma, Pronova and PhotoCur, and CSO Pål Rongved, Ph.D. in Medicinal chemistry and 22 years of leading positions in R&D/IPR at GE HealthCare and advisor to Birkeland Innovation. Adjutec Pharma was founded in 2019 in Oslo, Norway, and joined NOME in 2021.